Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723810 · ClinicalTrials.gov registry record · Phase 1
TumorGlow Intraoperative Molecular Imaging (IMI)
A Phase 1 study of Tumor, Solid, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT04723810 is a Phase 1 study of Tumor, Solid that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 500 participants, above the 198-participant average among 11 other Tumor, Solid trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04723810, a Phase 1 study of Tumor, Solid, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.
Conditions Studied
Interventions
- DRUG Indocyanine Green
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2027-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04723810
The ClinicalTrials.gov registry entry for NCT04723810 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 198-participant average among 11 other Tumor, Solid trials with a reported enrollment target (153% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumor, Solid appearing as the primary indexed condition, and to 1 intervention - of which Indocyanine Green is the first listed.
NCT04723810 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04723810 about?
NCT04723810 is a clinical study titled "TumorGlow Intraoperative Molecular Imaging (IMI)". This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided ...
What is the current status of trial NCT04723810?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2024-08-14. Estimated completion is 2027-01-14.
What conditions does trial NCT04723810 study?
This clinical trial studies the following conditions: Tumor, Solid.
What interventions are being tested in trial NCT04723810?
The interventions under investigation include: Indocyanine Green (DRUG).
Who is sponsoring clinical trial NCT04723810?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04723810 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor, Solid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
RECRUITING · Phase 1
-
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
RECRUITING · Phase 1
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.